Lilly, BI resubmit diabetes medication
Lilly and Boehringer Ingelheim are resubmitting their experimental SGLT2 diabetes medication empagliflozen to the FDA.
“We are very pleased to move forward . . . following a FDA inspection of the Boehringer Ingelheim facility,” BI president and CEO Paul Fonteyne said in a statement Tuesday, referring to the CRL that halted the FDA's review.
The European Commission greenlighted the diabetes medication, known as Jardiance, in May.